Mark Lampert: Stock Portfolio, Performance and Latest Trades
BVF Partners
13F portfolio value
$3.9B
44 holdings at Q2 2026
Get an email when Mark Lampert files a new 13F report
Free, no account needed. Unsubscribe with one click.
Mark Lampert's portfolio
As of Q2 2026, filed August 14, 2026 · prices as of October 8, 2026
| Company | Share of portfolio | Average buy price | Return | Current price | Last quarter |
|---|---|---|---|---|---|
| 14.2% | $35.43 | +431% | $188.12 | Added +3.8% | |
| 11.4% | $32.28 | +239% | $109.30 | Reduced −30% | |
Xoma Corp.98419J206 | 8.25% | $33.49 | — | — | Added +193% |
| 7.97% | $6.29 | +68.3% | $10.58 | No change | |
GH Research PLCGHRS | 5.95% | $20.14 | +1.5% | $20.45 | No change |
| 4.62% | $31.69 | −19.0% | $25.67 | Reduced −2.7% | |
| 4.27% | $44.94 | −9.2% | $40.80 | Reduced −6.6% | |
| 3.16% | $31.15 | +161% | $81.35 | Reduced −33% | |
Xencor Inc.XNCR | 2.94% | $17.12 | +43.1% | $24.50 | No change |
Alkermes PLCALKS | 2.89% | $31.60 | +26.9% | $40.11 | Added +7.7% |
| 2.76% | $8.29 | +24.5% | $10.32 | No change | |
| 2.68% | $20.31 | −23.9% | $15.46 | No change | |
| 2.63% | $33.84 | +288% | $131.34 | Reduced −30% | |
Zymeworks Inc.ZYME | 2.44% | $7.03 | +259% | $25.26 | Reduced −2.3% |
| 2.37% | $9.65 | +9.0% | $10.52 | No change | |
| 2.16% | $77.11 | −21.2% | $60.77 | Reduced −9.3% | |
| 2.13% | $21.96 | +9.1% | $23.95 | No change | |
| 1.69% | $36.73 | −78.7% | $7.82 | No change | |
Annexon Inc.ANNX | 1.27% | $2.79 | +43.4% | $4.00 | No change |
| 1.27% | $16.98 | −16.9% | $14.12 | No change | |
Ac Immune SAACIU | 1.21% | $4.31 | −40.8% | $2.55 | No change |
| 1.21% | $15.76 | +26.7% | $19.97 | Reduced −25% | |
| 1.06% | $18.07 | −15.2% | $15.32 | No change | |
| 1.05% | $32.08 | −9.3% | $29.09 | No change | |
| 0.98% | $11.94 | +12.5% | $13.43 | Added +27% | |
| 0.98% | $13.80 | −8.0% | $12.70 | No change | |
Q32 Bio Inc.QTTB | 0.77% | $12.74 | −36.5% | $8.09 | New |
| 0.76% | $5.74 | +15.4% | $6.63 | No change | |
| 0.73% | $5.91 | −66.3% | $1.99 | No change | |
Absci Corp.ABSI | 0.70% | $5.63 | +58.7% | $8.94 | New |
| 0.63% | $4.95 | −51.1% | $2.42 | No change | |
Invivyd Inc.IVVD | 0.63% | $1.83 | −61.7% | $0.70 | Added +44% |
| 0.49% | $6.80 | +31.2% | $8.92 | New | |
| 0.38% | $3.55 | −35.3% | $2.30 | Added +64% | |
Immunic Inc.IMUX | 0.30% | $12.33 | −38.7% | $7.56 | New |
| 0.27% | $3.42 | −18.4% | $2.79 | No change | |
| 0.17% | $11.38 | −62.6% | $4.26 | No change | |
| 0.14% | $2.33 | −90.2% | $0.228 | No change | |
| 0.14% | $10.43 | −1.2% | $10.30 | New | |
| 0.13% | $10.13 | −62.4% | $3.81 | No change | |
| 0.13% | $3.62 | — | — | No change | |
Entera Bio Ltd.ENTX | 0.11% | $1.25 | +99.8% | $2.50 | New |
| 0.07% | $13.36 | −75.1% | $3.32 | No change | |
| 0.01% | $0.2899 | −41.4% | $0.17 | New |
Mark Lampert's buys and sells
| Company | Action | Shares change | Value now |
|---|---|---|---|
| Added +6.6% | +340,909 | $240.1M | |
| Added +25% | +636,026 | $177.5M | |
| Sold out | −1,454,422 | — | |
| New | +1,024,288 | $32.1M | |
Verve Therapeutics Inc.92539P101 | Sold out | −6,904,050 | — |
| New | +1,387,863 | $22.4M | |
| Reduced −15% | −138,250 | $38.3M | |
Iteos Therapeutics Inc.46565G104 | Sold out | −3,075,000 | — |
| Reduced −1.3% | −35,180 | $140.5M | |
Rapt Therapeutics Inc.75382E109 | Sold out | −9,237,556 | — |
| New | +1,154,692 | $9.2M | |
Third Harmonic Bio Inc.88427A107 | Sold out | −2,372,933 | — |
| Sold out | −4,013,633 | — | |
Xoma Corp.98419J206 | Reduced −13% | −392,723 | $65.3M |
Immunic Inc.4525EP101 | Reduced −14% | −1,250,000 | $5.3M |
Allakos Inc.01671P100 | Sold out | −16,552,417 | — |
| Sold out | −5,228,461 | — | |
| Reduced −0.8% | −8,630 | $5.1M | |
Forte Biosciences Inc.34962G208 | Reduced −1.0% | −5,938 | $7.6M |
| Added +1.5% | +68,000 | $17.2M | |
Glycomimetics Inc.38000Q102 | Sold out | −9,544,262 | — |
Verastem Inc.VSTM | Added +62% | +1,303,957 | $14.1M |
| Sold out | −59,065 | — | |
| Added +6.9% | +336,600 | $7.6M |
Mark Lampert's portfolio by sector
Share of the stock portfolio at Q2 2026.
| Sector | Share |
|---|---|
| Health Care | 91% |
| Other | 8.3% |
| Industrials | 0.7% |
Portfolio performance: Mark Lampert vs. benchmarks
Your result if you had bought each reported portfolio on the day it was made public and held it until the next report, against the S&P 500 and Nasdaq-100.
- You, copying after each 13F filing – estimated value
- S&P 500
- Nasdaq-100
| Total return | Per year | |
|---|---|---|
| You, copying after each 13F filing – estimated value | +46.1% | +7.9% |
| S&P 500 | +89.0% | +13.6% |
| Nasdaq-100 | +113.3% | +16.4% |
Prices were available for 53% of the portfolio value on average; the rest is left out of the return.
Mark Lampert's most traded stocks
Quarters with a buy or a sell, all reports since Q2 2013.
| Company | Quarters bought | Quarters sold |
|---|---|---|
| 16 | 15 | |
| 14 | 15 | |
| 16 | 12 | |
| 12 | 13 | |
| 9 | 16 | |
| 13 | 11 | |
| 14 | 9 | |
| 14 | 9 | |
| 12 | 10 | |
| 9 | 13 | |
| 10 | 12 | |
| 13 | 9 | |
| 14 | 8 | |
| 8 | 13 | |
| 10 | 11 |